Inovio Pharmaceuticals, Inc.
INO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001055726
No open-market purchases or sales by Inovio Pharmaceuticals, Inc. insiders were filed in the last 90 days; 104 institutions reported holding it in 13F filings for Q2 2026, worth $36.1M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 11, 2026, 1:12 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $84.9M (130000.0% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 12, 2026 | Mar 18, 2025 | – | Mar 1, 2023 | – |
| Revenue | $65.3K | $217.8K | $832.0K | $10.3M | $1.77M |
| Operating expenses | $86.9M | $112.6M | $144.8M | $277.8M | $303.0M |
| Research and development | $54.2M | $75.6M | $86.7M | $187.7M | $249.2M |
| Selling, general and administrative | $32.7M | $37.0M | $47.6M | $90.2M | $53.8M |
| Operating income | -$86.8M | -$112.4M | -$143.9M | -$267.6M | -$301.2M |
| Interest expense | – | – | $1.22M | $1.25M | $1.94M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$84.9M | -$107.3M | -$135.1M | -$279.8M | -$303.7M |
| EPS, basic | $-1.81 | $-3.95 | $-6.09 | $-1.17 | $-1.45 |
| EPS, diluted | $-1.81 | $-3.95 | $-6.09 | $-1.17 | $-1.45 |
| Weighted shares, basic | 46.9M | 27.2M | 22.2M | 238.6M | 208.8M |
| Weighted shares, diluted | 46.9M | 27.2M | 22.2M | 238.6M | 208.8M |
| Margins and growth | |||||
| Operating margin | -132871.3% | -51616.9% | -17300.3% | -2607.4% | -16972.3% |
| Net margin | -130000.0% | -49254.3% | -16239.9% | -2726.7% | -17109.9% |
| Revenue growth, year over year | −70.0% | −73.8% | −91.9% | +478.2% | −76.1% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 12, 2026 | Mar 18, 2025 | – | Mar 1, 2023 | – |
| Cash and equivalents | $44.3M | $65.8M | $14.3M | $46.3M | $71.1M |
| Short-term investments | $14.2M | $28.3M | $131.0M | $206.7M | $330.2M |
| Accounts receivable | $450 | $1.20M | – | $1.70M | $5.47M |
| Total current assets | $61.1M | $97.8M | $153.1M | $315.2M | $448.4M |
| Property, plant and equipment | $2.53M | $3.66M | $4.96M | $7.73M | $17.5M |
| Goodwill | – | – | $0 | $10.5M | $10.5M |
| Intangible assets | – | – | $0 | $2.13M | $2.63M |
| Total assets | $74.3M | $113.2M | $171.0M | $348.5M | $495.9M |
| Total current liabilities | $43.7M | $35.3M | $42.6M | $96.9M | $65.7M |
| Total liabilities | $50.2M | $44.7M | $53.6M | $126.2M | $96.3M |
| Shareholders' equity | $24.1M | $68.5M | $117.3M | $222.4M | $399.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 12, 2026 | Mar 18, 2025 | – | Mar 1, 2023 | – |
| Operating cash flow | -$88.6M | -$104.1M | -$124.4M | -$216.2M | -$215.7M |
| Capital expenditures | $285.7K | $487.8K | $320.9K | $969.2K | $1.23M |
| Free cash flow | -$88.9M | -$104.6M | -$124.7M | -$217.2M | -$216.9M |
| Stock-based compensation | $3.76M | $6.60M | $11.1M | $22.6M | $26.3M |
| Investing cash flow | $14.0M | $104.1M | $87.4M | $109.6M | -$175.3M |
| Financing cash flow | $53.1M | $51.5M | $5.00M | $81.8M | $211.5M |
| Net change in cash | -$21.5M | $51.5M | -$32.0M | -$24.8M | -$179.6M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 5747.8% | 3028.7% | 1330.8% | 219.8% | 1484.0% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 10, 2026 | 187.3M | +249.6% | SEC |
| Aug 10, 2026 | 103.4M | +94.6% | SEC |
| May 12, 2026 | 82.3M | +124.3% | SEC |
| Mar 12, 2026 | 69.1M | +88.4% | SEC |
| Nov 7, 2025 | 53.6M | +105.3% | SEC |
| Aug 8, 2025 | 53.1M | +104.7% | SEC |
| May 9, 2025 | 36.7M | +41.5% | SEC |
| Mar 12, 2025 | 36.7M | +56.9% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-12 in Q1 2024.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.